BARCLAYS PLC - INOZYME PHARMA INC ownership

INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2023. The put-call ratio across all filers is 2.22 and the average weighting 0.3%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of INOZYME PHARMA INC
ValueSharesWeighting
Q3 2023$39
-30.4%
9,220
-9.7%
0.00%
Q2 2023$56
+55.6%
10,205
+62.7%
0.00%
Q1 2023$36
+414.3%
6,2730.0%0.00%
Q4 2022$7
-100.0%
6,273
-2.0%
0.00%
Q3 2022$17,000
-45.2%
6,4030.0%0.00%
Q2 2022$31,000
-13.9%
6,403
-26.7%
0.00%
Q1 2022$36,0008,7400.00%
Other shareholders
INOZYME PHARMA INC shareholders Q1 2023
NameSharesValueWeighting ↓
Pivotal bioVenture Partners Investment Advisor LLC 1,591,154$10,852,0004.54%
CHI Advisors LLC 892,057$6,084,0002.02%
Sofinnova Investments, Inc. 2,028,308$13,833,0000.81%
MPM BioImpact LLC 302,615$2,064,0000.38%
NEA Management Company, LLC 2,444,379$16,671,0000.34%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,344,786$15,991,0000.34%
Rock Springs Capital Management LP 868,466$5,923,0000.14%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,013,216$6,910,0000.13%
Orbimed Advisors 526,600$3,591,0000.05%
Overbrook Management Corp 16,726$114,0000.02%
View complete list of INOZYME PHARMA INC shareholders